Skip to main content

Table 5 Multivariate analysis

From: Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  RI NRM LFS OS GRFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Haplo vs MSD 0.66 (0.52–0.83) 0.0004 1.9 (1.43–2.53) < 0.0001 0.96 (0.81–1.14) 0.66 1.18 (0.96–1.43) 0.11 0.93 (0.79–1.09) 0.37
Age (per 10 years) 1.01 (0.94–1.08) 0.87 1.33 (1.21–1.47) < 0.0001 1.1 (1.05–1.17) 0.0004 1.19 (1.12–1.27) < 0.0001 1.11 (1.06–1.08) < 0.0001
Ph-neg B-ALL (ref)           
Ph-pos B-ALL 0.77 (0.63–0.95) 0.012 1.15 (0.86–1.54) 0.34 0.88 (0.75–1.14) 0.12 0.74 (0.61–0.9) 0.002 0.94 (0.82–1.08) 0.4
T-ALL 1.04 (0.85–1.26) 0.73 1.19 (0.87–1.62) 0.28 1.07 (0.91–1.26) 0.43 1.13 (0.94–1.36) 0.19 1 (0.86–1.15) 0.95
CR2 vs CR1 2.5 (2.08–3) < 0.0001 1.98 (1.5–2.62) < 0.0001 2.31 (1.99–2.7) < 0.0001 2.57 (2.17–3.06) < 0.0001 1.95 (1.69–2.24) < 0.001
Year of HSCT 0.99 (0.95–1.03) 0.64 0.94 (0.89–1.01) 0.074 0.98 (0.94–1.01) 0.17 0.96 (0.92–1) 0.082 1 (0.97–1.03) 0.98
Female to male vs. other 0.96 (0.8–1.15) 0.65 1.22 (0.94–1.57) 0.14 1.03 (0.88–1.19) 0.73 1.13 (0.95–1.34) 0.16 1.27 (1.12–1.45) 0.0002
MAC TBI (reference)           
MAC CT 1.32 (1.08–1.61) 0.006 1.03 (0.76–1.39) 0.87 1.22 (1.04–1.44) 0.016 1.1 (0.9–1.34) 0.34 1.05 (0.9–1.23) 0.54
RIC 1.61 (1.27–2.02) < 0.0001 0.62 (0.43–0.88) 0.007 1.18 (0.97–1.43) 0.095 0.99 (0.79–1.24) 0.92 1.02 (0.86–1.22) 0.82
Patient CMV positive 0.96 (0.79–1.18) 0.72 1.59 (1.15–2.19) 0.005 1.12 (0.95–1.33) 0.18 1.31 (1.07–1.6) 0.009 1.13 (0.97–1.31) 0.11
Donor CMV positive 1.21 (1.99–1.49) 0.063 0.86 (0.65–1.15) 0.32 1.09 (0.92–1.29) 0.3 1.01 (0.84–1.23) 0.89 1.01 (0.87–1.16) 0.94
Center (frailty)   0.32   0.031   0.31   0.064   0.007
  Acute GVHD grade II–IV Acute GVHD grade III–IV Chronic GVHD Extensive chronic GVHD
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Haplo vs MSD 1.53 (1.23–1.9) 0.0002 1.54 (1.1–2.15) 0.011 0.94 (0.74–1.18) 0.58 0.61 (0.43–0.88) 0.007
Age (per 10 years) 1.03 (0.96–1.1) 0.43 1.08 (0.97–1.2) 0.15 1.11 (1.03–1.18) 0.005 0.17 (1.06–1.29) 0.002
Ph-neg B-ALL (ref)         
Ph-pos B-ALL 0.93 (0.76–1.114) 0.49 1.15 (0.83–1.58) 0.4 0.82 (0.67–0.99) 0.041 1.03 (0.79–1.35) 0.83
T-ALL 0.88 (0.71–1.09) 0.24 0.94 (0.66–1.33) 0.73 0.84 (0.69–1.04) 0.11 0.99 (0.74–1.32) 0.94
CR2 vs CR1 1.11 (0.9–1.37) 0.31 1.34 (0.97–1.84) 0.078 1.25 (1–1.57) 0.051 1.55 (1.13–2.13) 0.006
Year of HSCT 0.96 (0.92–1) 0.053 1 (0.93–1.07) 0.96 0.96 (0.92–1) 0.044 1.04 (0.98–1.1) 0.23
Female to male vs. other 1.23 (1.02–1.47) 0.028 1.36 (1.03–1.82) 0.033 1.73 (1.46–2.05) < 0.0001 1.98 (1.57–2.5) < 0.0001
MAC TBI (reference)         
MAC CT 0.82 (0.65–1.04) 0.1 1.25 (0.9–1.75) 0.19 0.78 (0.62–0.98) 0.035 0.69 (0.49–0.96) 0.03
RIC 0.78 (0.61–1.01) 0.056 0.79 (0.53–1.19) 0.26 0.81 (0.63–1.04) 0.1 0.72 (0.5–1.04) 0.078
Patient CMV positive 1.01 (0.82–1.25) 0.93 1.34 (0.94–1.91) 0.1 1.04 (0.85–1.27) 0.69 1.17 (0.89–1.54) 0.27
Donor CMV positive 1.04 (0.85–1.28) 0.69 0.78 (0.56–1.08) 0.13 1.05 (0.86–1.27) 0.63 1.01 (0.77–1.31) 0.97
Center (frailty)   < 0.0001   0.1   < 0.0001   < 0.0001
  1. RI, relapse incidence; NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GVHD, graft versus host disease; GRFS, GVHD-free/relapse-free survival; MRD, minimal residual disease; ATG, anti-thymocyte globulin; PTCy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow